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S_ lThe retrospective analysis of 250 breast cancer patients with disseminated disease provided
evidence that the increase in CA 125 serum levels in these patients was caused by lung metastases or pleural
effusions. Seven patients with lung metastases and pleural involvement had elevated CA 125 levels, while in
four patients with lung metastases but without pleural effusions CA 125 levels remained normal. In patients
with only bone or liver metastases CA 125 levels were usually not elevated. If these results are confirmed, CA
125 would be the first tumour marker in breast cancer whose levels could be associated with one single site of
metastases.
Since 1986 we have measured CA 125 during follow-up of
breast cancer patients as part of the screening examinations
for genital cancer (Einhorn et al., 1992). During this period
we sometimes observed elevated levels of CA 125. Initially an
elevated CA 125 led to screening laparoscopy, which in some
of the patients revealed a peritoneal carcinomatosis or an
ovarian malignancy. However, in the vast majority of
patients the intra-abdominal findings were innocuous and
thus in the last few years we have stopped performing further
laparoscopy based on an elevated CA 125 level. Nevertheless,
these findings caused some uncertainty and we have therefore
tried to determine the reasons for the elevated CA 125 levels
in these patients.
Nearly all of the patients with elevated CA 125 levels
developed metastases. We therefore thought that the increase
in CA 125 was caused by the metastatic breast cancer cells.
However, this was difficult to accept, because the production
of CA 125 by breast cancer cells seemed to be the exception
and not the rule (Kabawat et al., 1983). In contrast, the
antigen is nearly always found on the surface of cells that
line the peritoneum, pericardium and pleura (Hardardottir et
al., 1990; de los Frailes et al., 1993). We thus hypothesised
that the increase in CA 125 in metastatic breast cancer is
caused by an infiltration of cancer cells into these tissues. In
order to test this hypothesis, we have analysed the serial
course of CA 125 by site of metastases.
Patie.s and methods
For this retrospective analysis only breast cancer patients
with a single site of metastasis were eligible (bone, liver or
lung). We never observed elevated CA 125 levels in patients
with isolated skin metastases and therefore this group was
excluded from the study. We established the following
patient inclusion criteria:
1. performance of bone scintigram, liver ultrasound and
chest radiograph at time of detection;
2. maximum of one metastasis detected through these pro-
cedures;
3. ovaries without suspicion of malignancy on pelvic ultra-
sound;
4. chest ultrasound excluding pericardial effusions;
5. no other metastases found with these same screening
procedures for at least 6 months after detection of the
first metastasis.
Serum samples from all these patients were obtained (and
stored deep-frozen) at the time of diagnosis of the metastasis
and 6 months before and after its detection. CEA and CA
15-3 measurements had been performed previously; CA 125
measurements were performed after thawing the serum sam-
ples. We used radioimmunoassays for the serum measure-
ments (ELSA CEA, ELSA CA 15-3, ELSA CA 125, ID-CIS,
Dreieich, Germany). The performance characteristics of these
assays have been described previously (Jager et al., 1991). All
samples were measured in duplicate. CA 125 concentrations
<35 kU 1' were considered as normal in post-menopausal
patients, <65 kU 1-1 in premenopausal patients (Jager et al.,
1988; Einhorn et al., 1992). Menopausal status was defined
according to FSH level at the time of detection of meta-
stases.
Results
Of a group of 250 patients with disseminated breast cancer,
only 26 fulfilled the inclusion criteria. Most patients were
excluded because multiple metastases were detected or could
not be ruled out within 6 months after the detection of the
first metastases. The final distribution of isolated metastases
in these 26 patients was as follows: bone = nine patients
(premenopausal: two patients), liver = six patients (premeno-
pausal: four patients) and lung= 11 patients (premenopausal:
five patients).
The CA 125 levels at the time of detection of these meta-
stases are shown in Figure 1. As can be seen, 7 of the 11
patients with lung metastases had elevated CA 125 serum
levels (three premenopausal and four post-menopausal
patients), while only one of nine patients with bone meta-
stases (post-menopausal patient) and one out of six patients
with liver metastases had high CA 125 levels (post-meno-
pausal patient). Of the seven patients with lung metastases
and elevated CA 125 levels, five had pleural effusions when
the metastases were detected. The other two patients
developed a pleuritis carcinomatosa with pleural effusions
within 4 weeks of the diagnosis of the lung metastasis. The
remaining four patients with normal CA 125 levels did not
develop pleural effusions. The patient with high CA 125
levels and bone metastasis was shown post mortem (7
months later) to have pleuritis carcinomatosa, which had not
been previously detected. The serial CA 125 measurements
showed that in some patients the CA 125 concentration
increased months before the detection of the metastasis
(Figure 2). In the one patient with a liver metastasis and
elevation of CA 125, the endocrine and metabolic function of
the liver was impaired. In this patient serum aspartate trans-
aminase (AST), serum alanine transaminase (ALT) and
serum glutamyl transferase (GGT) were elevated.
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Figre 1 CA 125 serum concentrations in patients with bone,
liver and lung metastases at the time of detection of metastases.
Stars indicate patients with pleural effusions. The shaded areas
denote the normal concentrations for post- (<35 kU 1 ') and
premenopausal (<65kUl') patients.
D
CA 125 has turned out to be an excellent tumour marker in
ovarian cancer (Jager et at., 1988; Bast et at., 1991). Elevated
levels of CA 125 have also been reported in patients with
metastatic breast cancer, and there has been disuassion con-
cerning its utility in this di (Perey et at., 1990; Tsavaris
et at., 1992). However, because an increase in CEA and CA
15-3 can indicate metastases n 80% of patients during
follow-up and the courses of these markers correlate accur-
ately with the clinical course of the disease, there apared to
be no indication for additional measurement of CA 125
(Jager et al., 1986; Colomer et at., 1989; Secel et at., 1992).
The results of this study have led us to reconsider this
opinion.
Onle objection to this new proposal could be that the
detection of a single metastasis cannot execlude other pre-
clinical metastases. The observed increase in CA 125 could
have also been caused by theeasothermicrometastases. It was
for this reason that we excluded patients in whom additional
metastases were found within 6 months of the first; it has
been demonstrated that in only 30% of patients will tumour
markers increase more than 6 months prior to detection of
metastases (Jager et al., 1991). However, the results found in
patients with bone and liver metastases made the interpreta-
tion of CA 125 levels in these patients much easier. They
suggest that elevation of CA 125 in metastatic breast cancer
patients is caused by lung metastases. Only one of nine
patients with bone metastases and one of six patients with
one liver metastasis had elevated CA 125 levels, yet in 7 of 11
patients with lung metastasis was this found to be the case.
Elevated CA 125 levels in primary lung cancer have been









Fge 2 Serial measurements of CA 125 serum levels before
detection of bone (0), liver (0) and lung (0) metastases, at the
time of detection and thereafter. The CA 125 levels are shown
only for those patients with elevated CA 125 levels at the time of
detection of metastases. The shaded areas denote the normal
concentrations for post- (<35 kU 1') and premenopausal
(<65 kU I-') patients.
Kandylis et al., 1990; Kimura et al., 1990; Diez et al., 1991).
In contrast, elevated levels of CA 125 in patients with bone
tumours have been reported only in patients with
disseminated metastatic disease; in primary bone cancer, e.g.
osteosarcoma, chondrosarcoma, giant cell tumour and
Ewing's tumour, CA 125 levels are normal (Shinozaki et al.,
1992; Tsavaris et al., 1992). We have thus concluded that the
increase in CA 125 in these breast cancer patients was caused
by the metastatic infiltration of either the lung or the pleura:
only in those patients with pleural involvement were CA 125
levels elevated; CA 125 levels in patients with no pleural
involvement remained low. This hypothesis is further sub-
stantiated by reports indicating that CA 125 levels are
elevated in patients with primary lung cancer predominantly
when the pleura is affected (Niwa & Shimokata, 1986, Van
Niekerk et al., 1989; Kandylis et al., 1990; Kimura et al.,
1990; Diez et al., 1991).
The decision to change treatment in diffius metastatic
breast cancer is usually based on the progression of the most
prominent metastases. If an increase in CA 125 levels in
breast cancer patients is caused by pleural metastases (or
lung metastases), then CA 125 measurement would permit
assessment of the response of this site to treatment. If CA
125 levels drop during therapy of metastatic breast cancer
then progression at another site should not necessarily lead
to a change of the whole treatment. It could instead lead to a
selective exchange of drugs. Since that would offer the
development of new treatment strategies, this observation
should be further investigated.
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